Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Gester (Liege, Belgium), M. Henket (Liege, Belgium), D. Deseny (Liege, Belgium), C. Moermans (Liege, Belgium), B. André (Liege, Belgium), M. Malaise (Liege, Belgium), R. Louis (Liege, Belgium), J. Guiot (Liege, Belgium). IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease. 3597

Member's Comments

No comment yet.

Related content which might interest you: Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis Source: Eur Respir J 2011; 38: 1355-1360 Year: 2011 The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin Source: Eur Respir J 2001; 18: 17S-29S Year: 2001 Predictors of progression in systemic sclerosis patients with interstitial lung disease Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019 Year: 2020 Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease Source: Eur Respir J, 53 (5) 1802182; 10.1183/13993003.02182-2018 Year: 2019 Clinical characteristics of interstitial lung fibrosis in progressive systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 95s Year: 2006 Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Interstitial lung disease in systemic sclerosis: where do we stand? Source: Eur Respir Rev 2015; 24: 411-419 Year: 2015 Expression of hyaluronidase by interstitial myofibroblasts and epithelial cells is associated with fibrosis extension, clinical forms and pulmonary function stage in patients with systemic sclerosis Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Disease course and outcome of progressive interstitial lung disease in systemic sclerosis Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Autoantibodies to the surfactant protein D in patients with interstitial lung diseases associated with amyopathic dermatomyositis and systemic sclerosis Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 CCL18 as marker of disease progression in systemic sclerosis Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012 Immunosuppression for interstitial lung disease in systemic sclerosis}, Source: Eur Respir Rev 2013; 22: 236-243 Year: 2013 Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017 Year: 2018 The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 543s Year: 2005